Screener
Sutro Biopharma STRO Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 9,707 | 10,903 |
| Other non-current assets | 1,088 | 495 |
| Restricted cash | 858 | 858 |
| Total assets | $241,988 | $173,830 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $5,485 | $7,565 |
| Accrued compensation | 5,354 | 14,642 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's total assets?
- Sutro Biopharma (STRO) reported total assets of $241.99M in Q1 2026.
- How has Sutro Biopharma's total assets changed year-over-year?
- Sutro Biopharma's total assets decreased by 24.7% year-over-year, from $321.43M to $241.99M.
- What is the long-term trend for Sutro Biopharma's total assets?
- Over 5 years (2020 to 2025), Sutro Biopharma's total assets has grown at a -15.1% compound annual growth rate (CAGR), from $394.11M to $173.83M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Sutro Biopharma's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude